S. Korea Set To Allow Resumption Of Embryonic Stem Cell Research
This article was originally published in PharmAsia News
South Korean Health Ministry and biotech industry officials reportedly have agreed to resume allowing stem cell research using cloned embryonic cells. They agreed the National Bioethics Committee would allow such research as early as April. The panel had delayed that decision earlier because a hospital that wanted to do similar research had not resolved controversial ethics issues. South Korea banned such research three years ago when it was revealed groundbreaking studies in the area had been fabricated. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.